503A compounds for a patient; 503B compounds for stock

This blog has already looked at what happens inside a conventional drug manufacturer’s own quality system once something goes wrong with a batch already in the field — the lab investigation an out-of-specification result opens, and the three-working-day report a distributed defect triggers. Both of those mechanisms assume the product came off a line built to current good manufacturing practice in the first place. A compounded drug doesn’t start from that assumption at all, and which of two statutory sections it’s compounded under decides whether CGMP applies to it as a baseline, or as something the compounder opted into.

Section 503A is a pharmacist’s exemption, tied to one patient

Section 503A of the Act exempts a licensed pharmacist or physician, compounding a drug for an individually identified patient based on a valid prescription or a documented patient-specific need, from three things that would otherwise apply to anyone making a drug product: current good manufacturing practice under section 501(a)(2)(B), the new-drug approval requirements of section 505, and the adequate-directions-for-use labeling requirement of section 502(f)(1). The exemption is conditioned on the compounding staying inside that patient-specific frame — it isn’t a general license to manufacture, it’s a carve-out for the specific case where a commercial product doesn’t fit what one named patient’s prescriber has ordered.

Interstate shipping carries its own separate limit

A 503A pharmacy that wants to ship compounded product across state lines runs into a second condition the exemption attaches on top of the patient-specific requirement: without a signed memorandum of understanding between FDA and the pharmacy’s home state, interstate distribution is capped at 5 percent of the pharmacy’s total prescription orders. FDA finalized a standard memorandum of understanding in 2020 that, for a state that signs it, raises the threshold the agency treats as an inordinate amount of interstate distribution to 50 percent instead. A pharmacy’s own exemption can turn on which side of that signature its home state falls, independent of anything about how carefully any individual prescription was compounded.

Section 503B trades the prescription for a registration

Section 503B, added by the Compounding Quality Act in 2013 after a fungal meningitis outbreak traced to a single compounding pharmacy, offers a different exemption to a different kind of facility. An outsourcing facility registers with FDA, pays an annual facility fee, and can compound without a patient-specific prescription in hand at all — filling a hospital’s office stock, for instance, ahead of any individual order. What it gives up in exchange is 503A’s own exemption from CGMP: an outsourcing facility has to compound under current good manufacturing practice, inspected by FDA on a risk-based schedule the way a conventional drug manufacturer is, rather than answering to a state board of pharmacy the way a 503A pharmacy does.

Both still answer to the same two restrictions

Neither section gives a compounder an unlimited menu of what to make. A drug compounded under either 503A or 503B can’t be “essentially a copy” of a commercially available product, and a bulk drug substance has to appear on one of FDA’s own lists — substances with a USP or NF monograph, components of an FDA-approved drug, or substances FDA has separately added to a 503B-specific bulks list after its own nomination and review — before either kind of facility can use it. A drug shortage loosens the copy restriction in both sections, but it doesn’t touch the bulk-substance restriction, which is a separate gate a shortage alone doesn’t open.

A facility can hold both roles, but not in the same breath

Nothing stops an outsourcing facility from also compounding patient-specific prescriptions, but FDA’s own guidance treats that as a second role requiring its own pharmacy registration, layered on top of the 503B outsourcing-facility registration rather than folded into it. A compounder operating both ways has to be clear, prescription by prescription, which exemption it’s actually relying on — because the CGMP obligation, the adverse-event reporting duty, and the bulk-substance list that apply depend on which section covers the specific product leaving the building, not on which registrations the facility happens to hold in general.

Where this meets the file

A compounding file that records only “503A” or “503B” as a single facility-level label has flattened a distinction the statute draws product by product and shipment by shipment. A compounding-oversight worksheet that keeps the applicable section, the MOU status behind any interstate shipment, and the bulk-substance list a given product draws from as separate required fields is previewed in the launch catalog alongside this week’s other drug-lifecycle templates. If your program tracks that distinction differently, the shelf takes that correction directly.